<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>.06 Policy Review—Process for Establishing a UPL. | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/14.01/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/14.01/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|14|01|05|.06|"/>
    <meta itemprop="doc-type" content="section" data-document=""/>
    <meta itemprop="doc-num" content=".06"/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="14|01|05|.06" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="/us/md/exec/comar/14.01.05.06"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content=".06 Policy Review—Process for Establishing a UPL. | Library of Maryland Regulations"/>
    <meta property="og:image" content="/us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/14.01/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/14.01/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14" data-search-heading="">
                  <a href="/us/md/exec/comar/14" title="Title 14 INDEPENDENT AGENCIES">Title 14 INDEPENDENT AGENCIES</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14|01" data-search-heading="">
                  <a href="/us/md/exec/comar/14.01" title="Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD">Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14|01|05" data-search-heading="">
                  <a href="/us/md/exec/comar/14.01.05" title="Chapter 05 Consumer Regulations">Chapter 05 Consumer Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14|01|05|.06" data-search-heading="">
                  <span title=".06 Policy Review—Process for Establishing a UPL.">.06 Policy Review—Process for Establishing a UPL.</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="14|01|05|.06">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/14.01.05.06">.06 Policy Review—Process for Establishing a UPL.</h1>
                <p class="text-indent-1 "><span class="level-num" id="A">A.</span> Staff Recommends Frameworks and Contextual Information.</p>
                <p class="text-indent-2 "><span class="level-num" id="A(1)">(1)</span> Board staff shall recommend at least one framework, identified in <a class="internal-link " href="/us/md/exec/comar/14.01.05.06#B" title="">§B of this regulation</a>, for use in developing a UPL for the subject prescription drug product.</p>
                <p class="text-indent-2 "><span class="level-num" id="A(2)">(2)</span> Board staff may recommend certain contextual information identified in <a class="internal-link " href="/us/md/exec/comar/14.01.05.06#C" title="">§C of this regulation</a> for use in developing a UPL for the subject prescription drug product.</p>
                <p class="text-indent-2 "><span class="level-num" id="A(3)">(3)</span> Board staff shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="A(3)(a)">(a)</span> Post staff’s recommendations on the Board’s website in advance of the Board meeting; and</p>
                <p class="text-indent-3 "><span class="level-num" id="A(3)(b)">(b)</span> Request public comment.</p>
                <p class="text-indent-2 "><span class="level-num" id="A(4)">(4)</span> The public may submit written comments by the date specified in the posting in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(4)" title="">COMAR 14.01.01.05B(4)</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="A(5)">(5)</span> Board staff shall present the recommendations to the Board.</p>
                <p class="text-indent-1 "><span class="level-num" id="B">B.</span> Frameworks.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(1)">(1)</span> Cost Effectiveness Analysis.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(1)(a)">(a)</span> Under this framework, a maximum UPL value may be set by:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(1)(a)(i)">(i)</span> Using a cost-effectiveness analysis to model how much additional health outcome is gained per dollar of additional spending when using a drug product compared to an alternative;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(1)(a)(ii)">(ii)</span> Comparing this number to a threshold to determine if a product is “cost-effective”; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(1)(a)(iii)">(iii)</span> Then, if the product is not already cost-effective, given the specified threshold in <a class="internal-link " href="/us/md/exec/comar/14.01.05.06#B(1)(a)(ii)" title="">§B(1)(a)(ii) of this regulation</a> and the model in <a class="internal-link " href="/us/md/exec/comar/14.01.05.06#B(1)(a)(i)" title="">§B(1)(a)(i) of this regulation</a>, calculating the maximum UPL for which it would be “cost-effective.”</p>
                <p class="text-indent-3 "><span class="level-num" id="B(1)(b)">(b)</span> When providing a UPL amount developed using this framework, Board staff shall identify the health outcome, threshold, and relevant underlying assumptions used in the analysis.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(2)">(2)</span> Therapeutic Class Reference Upper Payment Limit.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(a)">(a)</span> Under this framework, a UPL value may be set using the lowest net price or net cost among competitor products in the same therapeutic class.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(b)">(b)</span> The Board may limit the prescription drug products used for analysis to a subset of drugs in the same therapeutic class.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(c)">(c)</span> When determining whether to use a product in the same therapeutic class as a reference product, the Board may consider:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(2)(c)(i)">(i)</span> A difference in indication including a difference in the patient population and disease severity; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(2)(c)(ii)">(ii)</span> Comparative effectiveness research.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(3)">(3)</span> Launch Price-Based Upper Payment Limit.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(a)">(a)</span> Under this framework, a UPL value may be set based on the initial price at which the drug was first marketed (launch price) adjusted for inflation.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(3)(b)">(b)</span> The Board shall adjust the launch price using the CPI-U.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(4)">(4)</span> Same Molecule Reference Upper Payment Limit.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(4)(a)">(a)</span> Under the same molecule reference UPL framework, a UPL value may be set by comparing prices of certain reference drugs:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(4)(a)(i)">(i)</span> A generic drug product that is therapeutically equivalent to the product under the review;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(4)(a)(ii)">(ii)</span> An authorized generic of the product under review;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(4)(a)(iii)">(iii)</span> A drug product licensed under a BLA that has the same active ingredient and is approved for one or more of the same or similar indications as the product under review;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(4)(a)(iv)">(iv)</span> A biosimilar for the product under review;</p>
                <p class="text-indent-4 "><span class="level-num" id="B(4)(a)(v)">(v)</span> The reference product for the product under review; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(4)(a)(vi)">(vi)</span> A drug product approved under an NDA or ANDA that has the same active ingredient and is approved for one or more of the same or similar indications as the product under review.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(4)(b)">(b)</span> When using this framework Board staff may consider:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(4)(b)(i)">(i)</span> Any differences between the product under review and the same molecule reference products; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(4)(b)(ii)">(ii)</span> The utilization of the same molecule reference products.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(5)">(5)</span> Domestic Reference Upper Payment Limit.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(5)(a)">(a)</span> Under the domestic reference UPL framework, a UPL value may be set using the estimated net cost of a prescription drug product to other purchasers and payors for the same prescription drug product within the United States or the net price received by the manufacturer.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(5)(b)">(b)</span> Under this framework, the UPL may be set using the cost of the lowest estimated net-cost purchaser or payor, excluding Medicaid.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(5)(c)">(c)</span> The Board may consider information for all other payors, including information on the Medicare Maximum Fair Price.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(6)">(6)</span> International Reference Upper Payment Limit.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(6)(a)">(a)</span> Under the international reference UPL framework, a UPL value may be set by comparing drug prices in other countries.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(6)(b)">(b)</span> Under this framework, the Board may consider the lowest price received by manufacturers for sales in the United Kingdom, Germany, France, and Canada, converted to U.S. dollars.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(7)">(7)</span> Budget Impact-Based Upper Payment Limits.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(7)(a)">(a)</span> Under the budget impact-based UPL framework, a UPL value may be set so that spending on the drug does not exceed a certain percentage of a budget as specified by the Board or have a disproportionate impact on that budget.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(7)(b)">(b)</span> The Board may consider current spending, projected spending, and potential offsets in developing a UPL value.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(7)(c)">(c)</span> When setting the percentage, the Board may consider the number of patients impacted, the disease burden, the current and projected future spending on other treatments and management of the disease.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(8)">(8)</span> Blend of Multiple Frameworks.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(8)(a)">(a)</span> Under this framework, Board staff may recommend potential UPL values derived from:</p>
                <p class="text-indent-4 "><span class="level-num" id="B(8)(a)(i)">(i)</span> A blend of frameworks; and</p>
                <p class="text-indent-4 "><span class="level-num" id="B(8)(a)(ii)">(ii)</span> A variation in implementing a framework.</p>
                <p class="text-indent-3 "><span class="level-num" id="B(8)(b)">(b)</span> When providing a blended UPL amount developed using this framework, Board staff shall identify how the potential blended UPL value was generated.</p>
                <p class="text-indent-1 "><span class="level-num" id="C">C.</span> Contextual Information for the Prescription Drug Product:</p>
                <p class="text-indent-2 "><span class="level-num" id="C(1)">(1)</span> Information gathered during the cost review study process or the policy review process;</p>
                <p class="text-indent-2 "><span class="level-num" id="C(2)">(2)</span> Net costs for:</p>
                <p class="text-indent-3 "><span class="level-num" id="C(2)(a)">(a)</span> State health plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="C(2)(b)">(b)</span> County, bicounty, and municipal health plans;</p>
                <p class="text-indent-3 "><span class="level-num" id="C(2)(c)">(c)</span> Direct government purchases; and</p>
                <p class="text-indent-3 "><span class="level-num" id="C(2)(d)">(d)</span> Medicaid;</p>
                <p class="text-indent-2 "><span class="level-num" id="C(3)">(3)</span> Total out-of-pocket costs in:</p>
                <p class="text-indent-3 "><span class="level-num" id="C(3)(a)">(a)</span> State health plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="C(3)(b)">(b)</span> County, bicounty, and municipal health plans; and</p>
                <p class="text-indent-3 "><span class="level-num" id="C(3)(c)">(c)</span> Medicaid;</p>
                <p class="text-indent-2 "><span class="level-num" id="C(4)">(4)</span> Current coverage status of the drug in:</p>
                <p class="text-indent-3 "><span class="level-num" id="C(4)(a)">(a)</span> State health plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="C(4)(b)">(b)</span> County, bicounty, and municipal health plans; and</p>
                <p class="text-indent-3 "><span class="level-num" id="C(4)(c)">(c)</span> Medicaid;</p>
                <p class="text-indent-2 "><span class="level-num" id="C(5)">(5)</span> Utilization in the following program by patients and prescriptions:</p>
                <p class="text-indent-3 "><span class="level-num" id="C(5)(a)">(a)</span> State health plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="C(5)(b)">(b)</span> County, bicounty, and municipal health plans; and</p>
                <p class="text-indent-3 "><span class="level-num" id="C(5)(c)">(c)</span> Medicaid;</p>
                <p class="text-indent-2 "><span class="level-num" id="C(6)">(6)</span> Amount of direct government purchases by units and patients served;</p>
                <p class="text-indent-2 "><span class="level-num" id="C(7)">(7)</span> For the Maryland State Medical Assistance Program:</p>
                <p class="text-indent-3 "><span class="level-num" id="C(7)(a)">(a)</span> Number of prescriptions paid;</p>
                <p class="text-indent-3 "><span class="level-num" id="C(7)(b)">(b)</span> Number of patients who received the prescription drug product; and</p>
                <p class="text-indent-3 "><span class="level-num" id="C(7)(c)">(c)</span> Total amount paid for the prescription drug product;</p>
                <p class="text-indent-2 "><span class="level-num" id="C(8)">(8)</span> Budget impact analysis;</p>
                <p class="text-indent-2 "><span class="level-num" id="C(9)">(9)</span> Comparisons of health system costs to research and development costs;</p>
                <p class="text-indent-2 "><span class="level-num" id="C(10)">(10)</span> Life cycle revenue analysis; and</p>
                <p class="text-indent-2 "><span class="level-num" id="C(11)">(11)</span> Information that can be derived from the aggregation, calculation, and comparison of available information.</p>
                <p class="text-indent-1 "><span class="level-num" id="D">D.</span> UPL Values.</p>
                <p class="text-indent-2 "><span class="level-num" id="D(1)">(1)</span> The Board may:</p>
                <p class="text-indent-3 "><span class="level-num" id="D(1)(a)">(a)</span> Select one or more of the frameworks and contextual information identified in §§B and C of this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="D(1)(b)">(b)</span> Identify another framework;</p>
                <p class="text-indent-3 "><span class="level-num" id="D(1)(c)">(c)</span> Prioritize the selected and identified frameworks and contextual information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="D(1)(d)">(d)</span> Direct staff to use the selected and identified frameworks and contextual information to perform analyses and calculations to obtain UPL values.</p>
                <p class="text-indent-2 "><span class="level-num" id="D(2)">(2)</span> Based on guidance from the Board and the regulatory criteria under <a class="internal-link " href="/us/md/exec/comar/14.01.05.02" title=".02 Criteria for Setting an Upper Payment Limit.">Regulation .02 of this chapter</a>, Board staff shall perform calculations and analyses to develop a collection of potential UPL values.</p>
                <p class="text-indent-2 "><span class="level-num" id="D(3)">(3)</span> These calculations and analyses may include appropriate adjustments to ensure that the UPL value:</p>
                <p class="text-indent-3 "><span class="level-num" id="D(3)(a)">(a)</span> Reflects all discounts, rebates and price concessions;</p>
                <p class="text-indent-3 "><span class="level-num" id="D(3)(b)">(b)</span> Excludes dispensing and administration fees and direct and indirect renumeration to pharmacies; and</p>
                <p class="text-indent-3 "><span class="level-num" id="D(3)(c)">(c)</span> Includes patient out-of-pocket costs other than costs attributable to dispensing fees under <a class="internal-link " href="/us/md/exec/comar/14.01.05.06#D(3)(b)" title="">§D(3)(b) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="D(4)">(4)</span> Board staff shall post a public version of:</p>
                <p class="text-indent-3 "><span class="level-num" id="D(4)(a)">(a)</span> The UPL values developed through analysis;</p>
                <p class="text-indent-3 "><span class="level-num" id="D(4)(b)">(b)</span> Staff’s recommendation for a proposed UPL amount with a description of the calculation and analyses and relevant underlying assumptions used in the analysis such as health outcome or threshold; and</p>
                <p class="text-indent-3 "><span class="level-num" id="D(4)(c)">(c)</span> A request for public written comment on the Board’s website.</p>
                <p class="text-indent-2 "><span class="level-num" id="D(5)">(5)</span> Board staff may also request public written comment addressing specific questions or proposing alternative analyses.</p>
                <p class="text-indent-2 "><span class="level-num" id="D(6)">(6)</span> The public may submit written comments by the date specified in the posting in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(4)" title="">COMAR 14.01.01.05B(4)</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="E">E.</span> Technical Hearing.</p>
                <p class="text-indent-2 "><span class="level-num" id="E(1)">(1)</span> The Board may convene a hearing for the purpose of receiving technical input, technical information or expert testimony.</p>
                <p class="text-indent-2 "><span class="level-num" id="E(2)">(2)</span> The technical hearing shall be conducted in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.06" title=".06 Hearing Procedures.">COMAR 14.01.01.06</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="F">F.</span> Amendment of Recommendations and UPL Values.</p>
                <p class="text-indent-2 "><span class="level-num" id="F(1)">(1)</span> Board staff may modify or amend the public version of the developed UPL values, and staff’s recommendations for a proposed UPL amount.</p>
                <p class="text-indent-2 "><span class="level-num" id="F(2)">(2)</span> If Board staff modifies or amends the developed UPL values and staff’s recommendations, staff shall post the amendments to the Board’s website, and request public written comment by a specified date.</p>
                <p class="text-indent-2 "><span class="level-num" id="F(3)">(3)</span> The public may submit written comments by the date specified in the posting in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(4)" title="">COMAR 14.01.01.05B(4)</a>.</p>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/14.01.05.05" aria-label=".05 Policy Review—Preliminary Policy Recommendations.">
                <div class="h__ui">Previous</div>
                <span>.05 Policy Review—Preliminary Policy Recommendations.</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/14.01.05.07" aria-label=".07 Policy Review—Final Policy Action.">
                <div class="h__ui">Next</div>
                <span>.07 Policy Review—Final Policy Action.</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC-BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
